Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

Radiopeptide Therapy using Lu-177 3BP-227 in a Patient with Pancreatic Adenocarcinoma

Harshad Kulkarni, Christiane Schuchardt, Stefan Wiessalla, Christiane Smerling, Ulrich Reineke, Frank Osterkamp and Richard Baum
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1235;
Harshad Kulkarni
1THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Schuchardt
1THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Wiessalla
1THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christiane Smerling
23B Pharmaceuticals GmbH, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Reineke
23B Pharmaceuticals GmbH, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Osterkamp
23B Pharmaceuticals GmbH, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Baum
1THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1235

Objectives Neurotensin receptor subtype-1 (NTR1) is overexpressed in metastatic pancreatic adenocarcinoma, which has a very poor prognosis. Lu-177 labeled 3BP-227, an NTR1 antagonist, has been tested in preclinical models with promising results. We demonstrate dosimetric results in a case of pancreatic adenocarcinoma, treated with Lu-177 3BP-227.

Methods 59 year-old female patient with newly-diagnosed adenocarcinoma of the pancreatic head and lymph node metastases as well as peritoneal carcinosis with massive ascites (requiring thrice weekly asites tapping), s.p. 7 cycles of chemotherapy, received 1400 MBq Lu-177 3BP-227. Dosimetry was performed according to the MIRD scheme and using OLINDA/EXM software to estimate the dose to whole body, normal organs and metastases. Blood samples were drawn to determine the blood kinetics and to estimate the absorbed dose to red marrow.

Results Administration of Lu-177 3BP-227 was well tolerated without any significant adverse effects. Post-therapy planar and SPECT/CT images demonstrated significant uptake in the primary tumor. The whole body uptake showed a bi-exponential decline, half-lives being 5.8h and 30.5h. The kidneys followed an exponential clearance with a half-life of 50h. The primary tumor showed an exponential decline with half-life of 40h. The following mean absorbed doses were calculated: whole body: 0.1Gy, kidneys: 1.5Gy, primary: 1Gy, red marrow was 0.12Gy. Follow-up CT 8 weeks after therapy demonstrated a decrease in size of the primary tumor. There was no significant fall in the blood counts and serum creatinine or any of the other laboratory parameters.

Conclusions Radiopeptide therapy with higher activity of Lu-177 3BP-227 is feasible in adenocarcinoma of the pancreas with exhaustion of therapy options. Lu-177 3BP-227 holds great promise for treatment of this highly aggressive cancer.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Radiopeptide Therapy using Lu-177 3BP-227 in a Patient with Pancreatic Adenocarcinoma
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Radiopeptide Therapy using Lu-177 3BP-227 in a Patient with Pancreatic Adenocarcinoma
Harshad Kulkarni, Christiane Schuchardt, Stefan Wiessalla, Christiane Smerling, Ulrich Reineke, Frank Osterkamp, Richard Baum
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1235;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Radiopeptide Therapy using Lu-177 3BP-227 in a Patient with Pancreatic Adenocarcinoma
Harshad Kulkarni, Christiane Schuchardt, Stefan Wiessalla, Christiane Smerling, Ulrich Reineke, Frank Osterkamp, Richard Baum
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1235;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • The frequency and content of documentation for patients’ 131I therapies for checkpoint security agents: the final report of a national survey.
  • Comparing two methods for 90Y PET based dosimetry as a predictor of metabolic response for patients receiving radioembolisation
Show more Oncology: Basic, Translational & Therapy

MTA I: Radiopharmaceutical Therapy Posters

  • The frequency and content of documentation for patients’ 131I therapies for checkpoint security agents: the final report of a national survey.
  • Comparing two methods for 90Y PET based dosimetry as a predictor of metabolic response for patients receiving radioembolisation
  • Radiosensitization effect of bromodomain overexpression on thyroid anaplastic tumor using human applicable low iodine-131 dose
Show more MTA I: Radiopharmaceutical Therapy Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire